Terms: = Cervical cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Treatment
11 results:
1. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids.
Dong J; Holthaus D; Peters C; Koster S; Ehsani M; Quevedo-Olmos A; Berger H; Zarobkiewicz M; Mangler M; Gurumurthy RK; Hedemann N; Chumduri C; Kabelitz D; Meyer TF
Front Immunol; 2023; 14():1281646. PubMed ID: 38090581
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
[TBL] [Abstract] [Full Text] [Related]
3. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
4. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carroll MR; Ramalingam P; Salvo G; Fujimoto J; Solis Soto LM; Phoolcharoen N; Hillman RT; Cardnell R; Byers L; Frumovitz M
Int J Gynecol Cancer; 2020 Sep; 30(9):1303-1307. PubMed ID: 32727929
[TBL] [Abstract] [Full Text] [Related]
6. Metastatic rectal cancer to papillary thyroid carcinoma: a case report and review of literature.
Luo M; Huang Y; Li Y; Zhang Y
BMC Gastroenterol; 2020 May; 20(1):136. PubMed ID: 32375670
[TBL] [Abstract] [Full Text] [Related]
7. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract] [Full Text] [Related]
8. Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.
Real NE; Castro GN; Darío Cuello-Carrión F; Perinetti C; Röhrich H; Cayado-Gutiérrez N; Guerrero-Gimenez ME; Ciocca DR
Cell Stress Chaperones; 2017 Nov; 22(6):811-822. PubMed ID: 28608263
[TBL] [Abstract] [Full Text] [Related]
9. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized cancer Therapy at UC San Diego Moores cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract] [Full Text] [Related]
10. Project for the National Program of Early Diagnosis of Endometrial cancer Part I.
Bohîlțea RE; Ancăr V; Cirstoiu MM; Rădoi V; Bohîlțea LC; Furtunescu F
J Med Life; 2015; 8(3):305-14. PubMed ID: 26351531
[TBL] [Abstract] [Full Text] [Related]
11. Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128.
Zempolich K; Fuhrman C; Milash B; Flinner R; Greven K; Ryu J; Forbes A; Kerlin K; Nichols RC; Gaffney DK
Gynecol Oncol; 2008 May; 109(2):275-9. PubMed ID: 18299147
[TBL] [Abstract] [Full Text] [Related]
